|
Tuesday
|
| |
|
|
|
| 18:30-21:30 |
Registration at the Conference Venue |
| |
|
|
|
| |
|
|
|
| 18:30-21:30 |
Opening Ceremony, Welcome Reception |
| |
|
|
|
|
|
|
Wednesday
|
| |
|
|
|
| 8:00-8:45 |
Registration at the Conference |
| |
|
|
|
| |
|
|
|
| 8:45-9:00 |
Welcome and Introduction |
Oscar Della Pasqua and Thomas Dorlo
|
| |
|
|
|
| 9:00-10:00 |
New Modeling Approaches |
Marylore Chenel & Rob ter Heine
|
| |
|
|
|
| 9:00-9:20 |
Nikolaos Alimpertis |
The estimates for the absorption rate constant in pharmacokinetics and pharmacometrics are wrong: A new era based on the finite absorption time concept rises |
| |
|
|
|
| 9:20-9:40 |
Robin Chaux |
Meta-analysis of parameter estimates of non-linear mixed effect models using Approximate Bayesian Computation: application to population pharmacokinetics |
| |
|
|
|
| 9:40-10:00 |
Mohamed Gewily |
A Semi Parametric Method for the Estimation of End of Treatment Effect |
| |
|
|
|
| 10:00-11:30 |
Coffee Break, Software, and Poster Session I |
| |
|
|
|
| |
|
|
|
| 11:30-12:30 |
Pediatric Extrapolation |
Kristin Karlsson, Nick Holford, & Rocio Lledo
|
| |
|
|
|
| 11:30-11:50 |
Kristin Karlsson |
Paediatric Extrapolation - Opportunities and Challenges |
| |
|
|
|
| 11:50-12:10 |
Italo Poggesi |
Extrapolating treatment to children less than 6 years old: the successful story of velmanase alfa in alpha-mannosidosis |
| |
|
|
|
| 12:10-12:30 |
Bart van Lieshout |
Population pharmacokinetic analysis of guanabenz in children with Vanishing White Matter: Evaluating scaling adult drug safety and pharmacokinetics data |
| |
|
|
|
| 12:30-14:00 |
Lunch |
| |
|
|
|
| |
|
|
|
| 14:00-14:50 |
A tutorial on machine learning & pharmacometrics |
Gilbert Koch & Martin Bergstrand
|
| |
|
|
|
| 14:00-14:50 |
Nadia Terranova and Uri Nahum |
Artificial Intelligence and Machine Learning for Next-Generation Model-Informed Precision Medicine: A Tutorial on Practical Applications and Pitfalls |
| |
|
|
|
| 14:50-15:30 |
Machine Learning in Pharmacometrics |
Gilbert Koch & Martin Bergstrand
|
| |
|
|
|
| 14:50-15:10 |
Antari Khot |
Do tree-based machine learning methods outperform Cox regression for progression-free survival prediction in mobocertinib treated lung cancer patients? |
| |
|
|
|
| 15:10-15:30 |
Ana Victoria Ponce Bobadilla |
Benefits of integrating machine learning with clinical pharmacology principles for predictive pharmacokinetic modeling |
| |
|
|
|
| 15:30-15:35 |
RedIF Announcement |
Darlene Santiago
|
| |
|
|
|
| 15:35-17:00 |
Coffee Break, Software, and Poster Session II |
| |
|
|
|
| |
|
|
|
| 17:05-17:45 |
Neurodegenerative diseases |
Monica Simeoni
|
| |
|
|
|
| 17:05-17:25 |
Alzahra Hamdan |
Item Response Theory Analysis of the Scale for the Assessment and Rating of Ataxia in Autosomal Recessive Cerebellar Ataxias |
| |
|
|
|
| 17:25-17:45 |
Alessio Paris |
An age-dependent QSP model of Nf trafficking to optimize treatment in neurodegenerative diseases |
|
|
|
Thursday
|
| |
|
|
|
| 8:30-10:10 |
Lewis Sheiner Student Session |
Paolo Denti, Maria Kjellsson, and Stefanie Hennig
|
| |
|
|
|
| 8:30-8:55 |
Conor O'Hanlon |
A framework for drug pharmacokinetics during cardiopulmonary bypass |
| |
|
|
|
| 8:55-9:20 |
Alexander Janssen |
A generative and causal pharmacokinetic model for haemophilia A: towards an unified model for all factor VIII concentrates. |
| |
|
|
|
| 9:20-9:45 |
Alessandro De Carlo |
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat |
| |
|
|
|
| 9:45-10:10 |
Alexandra Lavalley-Morelle |
Joint modeling of biomarkers dynamics and survival with competing risks to predict the prognostic of patients hospitalized with severe infectious diseases |
| |
|
|
|
| 10:10-10:15 |
Presentation Lewis Sheiner Student Session Awards |
| |
|
|
|
| |
|
|
|
| 10:15-11:45 |
Coffee Break, Software, and Poster Session III |
| |
|
|
|
| |
|
|
|
| 11:45-12:25 |
Modelling Antibody Responses |
Thomas Dorlo
|
| |
|
|
|
| 11:45-12:05 |
Iñaki F. Trocóniz |
Modeling the dynamics of anti-drug antibodies in cancer patients treated with oncolytic virus in monotherapy or in combination with immune check- point inhibitors |
| |
|
|
|
| 12:05-12:25 |
Quentin Clairon |
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2 vaccine |
| |
|
|
|
| 12:25-13:55 |
Lunch |
| |
|
|
|
| |
|
|
|
| 13:55-14:40 |
Keynote Lecture |
Dinesh de Alwis & Lena Friberg
|
| |
|
|
|
| 13:55-14:40 |
Alexandra Snyder |
Current and future applications of circulating tumor DNA (ctDNA) to oncology drug development |
| |
|
|
|
| 14:40-15:20 |
Tumor Growth Dynamics |
Dinesh de Alwis & Lena Friberg
|
| |
|
|
|
| 14:40-15:00 |
Yomna Nassar |
A joint tumour dynamics and C-reactive protein turnover model to identify early longitudinal prognostic predictors of overall survival in advanced non-small cell lung cancer patients |
| |
|
|
|
| 15:00-15:20 |
Anna Kondic |
The combined use of propensity score matching and a joint tumor growth dynamics (TGD) - Overall Survival (OS) model to benchmark the efficacy of new treatments for advanced renal cell carcinoma (RCC) |
| |
|
|
|
| 15:20-15:25 |
ACoP Announcement |
Wei Gao
|
| |
|
|
|
| 15:25-16:55 |
Coffee Break, Software, and Poster Session IV |
| |
|
|
|
| |
|
|
|
| 16:55-17:55 |
Stuart Beal Methodology Session |
Ana Ruiz
|
| |
|
|
|
| 16:55-17:15 |
Freya Bachmann |
Computing Optimal Drug Dosing with Constraints on Model States in NONMEM |
| |
|
|
|
| 17:15-17:35 |
Dominic Bräm |
Neural ODE structures based on pharmacokinetic principles |
| |
|
|
|
| 17:35-17:55 |
Zhonghui Huang |
Development and exploration of exhaustive, stepwise, and heuristic algorithms for automated population pharmacokinetic modelling |
| |
|
|
|
| 20:30-2:00 |
Social Event |
| |
|
|
|
|
|
|
Friday
|
| |
|
|
|
| 9:15-10:15 |
QSP & PBPK Disease Models |
Oscar Della Pasqua
|
| |
|
|
|
| 9:15-9:35 |
Joey Leung |
Virtual population analysis of a Quantitative Systems Pharmacology (QSP) model of atopic dermatitis (AtD) to evaluate AtD treatments |
| |
|
|
|
| 9:35-9:55 |
Natalia Riva |
Expanding a quantitative systems pharmacology (QSP) modeling framework for acute Hepatitis B to characterize chronic infection |
| |
|
|
|
| 9:55-10:15 |
Robin Michelet |
Development and Application of a Minimal Physiology-based Pharmacokinetics Modelling Framework to Predict Tumor Penetration and Receptor Occupancy. |
| |
|
|
|
| 10:15-10:20 |
Preview of PAGE 2024 |
| |
|
|
|
| |
|
|
|
| 10:20-10:55 |
Coffee Break |
| |
|
|
|
| |
|
|
|
| 10:55-11:55 |
Model Diagnostics |
Siv Jönsson
|
| |
|
|
|
| 10:55-11:15 |
Martin Bergstrand |
Application relevant shrinkage metrics |
| |
|
|
|
| 11:15-11:35 |
Sarah Baklouti |
Multivariate Exact Discrepancy : a new tool for PK/PD model evaluation |
| |
|
|
|
| 11:35-11:55 |
Stefanie Hennig |
Considerations when deriving time-averaged exposure for censored subjects for logistic regression exposure-response analyses |
| |
|
|
|
| 11:55-12:05 |
Closing remarks |
| |
|
|
|
| |
|
|
|
| 12:05-12:20 |
Audience Input for potential PAGE 2024 topics |
| |
|
|
|
